Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Development Prospecting: Will Sirtris' Pipeline Pay Dividends at FDA?

This article was originally published in RPM Report

Executive Summary

GlaxoSmithKline went out on a limb by paying $720 million for Sirtris' relatively untested enzyme technology. How FDA evaluates the first-in-class therapy will determine whether GSK was pound wise or pound foolish. Two former FDA reviewers weigh in on how the company can make the most from its investment.
Advertisement

Related Content

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080436

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel